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INTRODUCTION
In developed countries, coronary artery disease
remains a major cause of mortality amongst people
over 45 years. It has been confinned that some factors
such as cigarette smoking, diabetes mellitus, hyper-
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tension, hyperlipideamia promote atherosclerosis.
Androgens and especially testosterone are considered
responsible for the much higher rate of coronary
artery disease in men (2). Several findings appear
to support this. The male gender is an independent
coronary artery disease risk factor (3, 4). There have
been some reports concerning deaths of young body-
builders overdosing with synthetic androgens (5).
These stereotyped opinions on the role of androgens
in cardiology had to be changed according to more
recent findings published within the past 5 years.
In rats, castration per se resulted in a significant
increase in aortic atherosclerosis (6). An adverse correla-
tion between endogenous testosterone levels and
the extensiveness of coronary atherosclerosis has
been demonstrated in just one study (7). Some findings
indicate that endogenous androgens play a protective
role mostly by modulating some risk factors such as
lipid profile, hypertension, insulin resistance, fibrinolysis
and modulating cytokin levels (8 -10).
Previous studies suggested that testosterone may
improve symptoms and postexercise ST depression
in patients suffering from angina pectoris (11, 12).
The vasodilator properties of endogenous male sex
hormone have been demonstrated in animal studies
(13 -15). In humans, testosterone enhances relaxation
of the brachial artery (16) and in the coronary artery
bed, it produces dilatation and increases blood flow
(17, 18). These effects are apparent even with low-
doses of testosterone (19).
There are only few laboratory findings suggesting
the positive effects of testosterone on left ventricular
function. Ejection fraction reduction, diastolic dysfunction
develop following gonadodectomy in male rats (20).
In the present study, we investigated the associations
between endogenous sex hormone levels and the
extensiveness of coronary atherosclerosis, left ventricle
ejection fraction and coronary heart disease risk
factors.
METHODS
Study design. Included in the study were100Caucasian
men who had had X-ray coronary angiography with
left venticulography performedatThe InvasiveCardiology
Department. Our research was approved by the Local
Bioethics Commission.
Before angiographic evaluation blood samples were
drawn between 8 a.m. and 10 a.m. All had determined
total testosterone, free testosterone, free androgen
index (FAI), sex hormone-binding globulin (SHBG),
oestradiol, luteinizing hormone, follicle-stimulating
hormone, total cholesterol, high-density lipoprotein, low-
density lipoprotein, triglycerides, partial thromboplastin
time, prothrombin time, fibrinogen, glucose. Blood
samples were then centrifuged and frozen below
-20℃.
The following variables were noted during the
examination:age, history of hypertension, diabetes
mellitus, cigarettes smoking, behaviour pattern A
(interviewed by a psychologist), hyperlipideamia,
medications (statin therapy), family history of coronary
heart disease, previous myocardial infarction.
Weight, height, systolic and diastolic bloodpressures
(mean of 5 consecutivemeasurements) were estimated.
The same physicianperformedallmeasurements. Body
Mass Index was calculated using the formula BMI=
weight (kg)/height (m2).
Participants : 100men aged 32-72 years, mean54,
were recruited. The inability of proper data collection
resulted in the exclusion of 4men. Elimination criteria
were : taking medication influencing sex hormone
levels, past history of hypogonadism, thyrotoxicosis,
hypothyroidism, restrictive cardiomyopathy, congenitive
dyslipidaemia,myocardial infarctionwithin onemonth
before the investigation, homocysteinaemia, pacemaker,
previous coronary angioplasty and bypass surgery,
valvular heart disease.
Quantative Coronary Angiographymodule ofMDQM
Medcon was used to evaluate the extensiveness of
coronary lesions. The patients were divided into two
groups on the basis of atherosclerosis extensiveness
according to the Duke Prognostic CAD Index. It is
a prognostic measure related to the anatomic extent
and severity of the atherosclerotic involvement of the
coronary tree. It was designed to overcome some of
the deficiencies of the number of diseased vessels
classification. Duke Index is labelling the patient with
the worst category applicable upon the estimation of
the prognostically important data about lesion severity
and its localization. The final index ranges from“0 to
100.”
In the patient group (Group I) 76 patients had at
least a 50 percent lesion of at least one vessel (Duke
Index＞19%).
In the control group (GroupⅡ) therewere 20patients
without any lesions in the coronary arteries (Duke
Index 0). Those patients had positive exercise test
results, non-characteristic chest pains and the normal
velocity of blood flow within the coronary arteries.
Left ventricle ejection fraction was calculated in
ventriculography for every single patient using Left
Ventricular Analysis module of MDQM Medcon on
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the TCSTM Acquisition workstation, Medcon In the
group with lesions were categorized in accordance
with the guidance of the American Heart Association
Classification of lesion type (21).
Laboratory techniques : All tests were performed
at The Local Municipal Hospital.
Serum sex hormone binding globulin (inter-assay
coefficient of variation 10.6% and 8.9% at 5.2 nmol/L
and 73nmol/L), sensitivity 0,23 nmol/L, oestradiol
(variation of 14.8% at 191 pmol/L and 8.1% at 2830
pmol/L) with a sensitivity of 16 pmol/L, free (with
an inter-assay coefficient of variation 5.2% at 15.6 pmol/
L and 3.1% at 143 pmol/L), with a sensitivity of 12 pmol/
L and total testosterone (inter-assaycoefficientof variation
7.8% and 5.6% at 3.3 nmol/Land16.9nmol/L, respectively)
with sensitivity of 0.23 nmol/L levels weremeasured by
chemiluminescence in enzyme-immuno-assays (Bayer
ACS-180, TheChironDiagnostics ACS : 180 Automated
Chemiluminescence Systems).
The enzymatic method was used to assess lipid
levels (KoneLab 30, Bio-Merie). All patients had their
free androgen index calculated (total testosterone/
sex hormone binding globulin (100). Fibrinogen levels
were assessed ons a CAM-MTX apparatus (Organon).
Statistical analyses : Values are expressed as mean±
1SD or percentages where appropriate. Pearson’s
linear correlation coefficient was calculated to test
correlations and significance of variables. In the case
of a nonlinear value of variables the Spearmancorrelation
test was performed. The Kologorov-Smirnov test was
used to evaluate the data distribution. Groups comparison
was performed using t testwhen thedatawere normally
distributed and the Mann-Whitney U nonparametric
test when they were not. Chi-square Pearson test for
an unpaired model was used to evaluate the statistical
correlation of the data shown in Table 1.
Assessment of a statistical correlation between
left ejection fraction and sex hormone levels wasmade
after excluding patients with MI (Mann-Whitney U
test) (Table 3).
Statistical analyses were performed using the SPSS
package, release 8.0.0pl (SPSS. Chicago, IL), with a
level of significance of 5%.
RESULTS
Baseline clinical characteristics of the two groups
are given in Table 1. Mean age andBodyMass Index
were higher in the patient group, however, they were
not significantly different. Only cigarette smoking and
hypercholesterolaemia as coronary artery disease risk
factors were significantly different,whereasother factors
(diabetesmellitus, hypertension, age, behaviour pattern
A) were not. A past history of myocardial infarction
was characterised only in subjects with coronary heart
disease.
Seventy-two percent of the men in group 1 were
current smokers. Total testosterone and SHBG varied
significantly in the current smokers, whereas free-
testosterone and FAI did not. In the smokers cohort
the means of total testosterone, SHBG and oestradiol
were 17.3 nmol/L, 41.9 nmol/L, 118.8 pmol/L,whereas
the correspondingmeans in the non-smokers (11 cases)
were 15.5 nmol/L (p<0.005), 36.8 nmol/L (p<0.05),
111.6 pmol (p<0.05).Smokers had significantly higher
levels of total testosterone, SGBH and oestradiol.
After adjustment for age and cigarette smoking only
the levels of total testosterone, free-testosterone, FAI
and oestradiol were significantly lower in the patients
group (Table 2).
There were no significant differences in the levels
of total cholesterol or LDL between the groups. Subjects
with CAD (coronary artery disease) had lower HDL
levels, whereas levels of TG were higher.
Subjects fromwithinCADcohorthadhigherSBP,DBP,
and significantly lower left ventricular ejection fraction
(Table 2). After excluding the cases with myocardial
infarction and after adjustment for confounders : age,
hypertension, cigarette smoking, and the difference in
ejection fraction became lower but were still significantly
different (cases 51.85 [SD 8.22] vs controls 61.30 [23.37]
(Table 3). The same trendwas observedwith hormone
Table 1. Coronary heart disease risk factors comparison
between patients and controls.
patients (n＝７６） controls (n＝２０） p
Age [SD](Min-Max)
Behaviour pattern A
BMI [SD](Min-Max)
MI history
Diabetes mellitus
Hypertension
Hipercholesterolaemia
Cig. smoking
Statin therapy
５４．７［１８．７］（４３‐７２）
２８
２７．９７［１４．４］（１９‐３５）
３６
１０
４４
６０
５５
３０
４８．２［１７．４］（３２‐５４）
８
２６．３２［１２．５］（２５‐３３）
０
２
１６
８
８
８
０．０８６
０．７９５１
０．５１３
０．０００１
０．１６４５
０．０７６２
０．００１２
０．００２４
０．０６５３
BMI-Body Mass Index
Cig. smoking-Cigarette smoking
MI history-Myocardial infarction history
Max-maximum value
Min-minimum value
p-statistical significance
SD-standard deviation
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levels, which were slightly lower in cases without
MI compared with controls.
In haematological examination, only fibrinogen
was essentially higher in CAD patients (Table 2).
In both groups FAI and free-testosterone were
negatively associated with HDL, while SHBG and
oestradiol were positively associated with HDL (Table
4). FAI and free-testosteronewere positively associated
with triglycerides, while SHBG negatively. FAI and
free-testosterone negatively associatedwith SBP, DBP
and fibrinogen. Free testosterone levels were negatively
associated with the degree in the Duke Index whereas
none of the hormones correlated with lesion type
(Spearman correlation coefficient) (data not shown).
DISCUSSION
In the present study, men with coronary heart
disease were found to have significantly lower levels
of endogenous sex hormones than males without
any atherosclerotic lesions in the coronary bed.
Two groups of patients were investigated. Group 1
consisted ofmenwith lesionsdocumented in angiograms,
with a Duke Index greater than 19%. Patients with no
evidence of atherosclerotic lesions were included in
group 2. Not surprisingly these groups differed from
each other significantly by several coronary risk factors
(see Table 1). However, after adjustment for confounders,
endogenous sex hormone levels remained essentially
lower in men with proven coronary heart disease (table
2). Moreover, free testosterone levels were negatively
correlatedwith the extensivenessof atherosclerosis in the
coronary bed (5). Several prior studies investigating the
possibilities of such associationshave reported conflicting
Table２. Comparison of laboratory findings between patients
and controls.
Patients n＝７６
[SD]
(Min‐Max)
Controls n＝２０
[SD]
(Min‐Max)
p
Total testosterone
(NR７．５‐３７．０）nmol/L
Free testosterone
(NR３７．４‐１３８．７pmol/L)
Free androgen index
(NR１８‐５０IU)
Oestradiol
(NR＜１８０pmol/L)
SHBG
(NR１５‐７５nmol/L)
LH
(NR１．３‐９．１IU/L)
FSH
(NR１．７‐１２．６IU/L)
Total cholesterol
(NR＜５．２０mmol/L)
LDL
(NR＜３．３６mmol/L)
TG
(NR＜１．８mmol/L)
HDL
(NR＞１．８mmol/L)
SBP mmHg
DBP mmHg
EF
(NR＞７５％）
Fibrinogen
(NR２００‐４００mg/L)
１１．９［４．８］
（２．０‐１９．９）
４５．５３［１６．３９］
（３５．００‐５６．００）
３６．７［１２．７］
（１２‐４７）
１０９．４［５６．７］
（２７．０‐２４５．４）
３４．３５［１０．２］
（１８．００‐５０．００）
３．７４［１．６７］
（２．３２‐５．２０）
５．９３［１．８２］
（４．１２‐２８．００）
５．６６［２．３１］
（２．５６‐１２．５３）
３．４６［１．３８］
（３．３５‐６．８６）
２．１１［０．８６］
（０．６２‐４．８）
１．０６［０．４７］
（０．５９‐２．２０）
１３８．２５［５２．８２］
（１２０‐２１０）
８６．２５［３１．０９］
（１１０‐５５）
４９．８０［１８．４４］
（３３．００‐６５．００）
３８６．５４［５４．７７］
（２４０‐４６８．００）
２１．２［７．４］
（１５．７‐２６．８）
８６．１０［２８．４９］
（５４．００‐６７．００）
４７．３［１７．８］
（２１‐４９）
１４６．４［６６．５］
（８０．４‐１８４．０）
３１．３５［１３．２８］
（２３‐４０）
３．５６［１．６９］
（２．２８‐４．４３）
５．４５［０．８６］
（４．２６‐６．５４）
５．３１［２１．７７］
（４．５３‐６．７５）
３．２６［１．７８］
（３．１０‐３．７５５）
１．５９［０．９６］
（１．０１７‐３．８９）
１．１６［０．４８］
（１．０３‐１．２９）
１３３．１３［４８．５５］
（１１０‐１５０）
８１．０９［２８．３５］
（１００‐８０）
６１．３０［２３．３７］
（５６．００‐６５．００）
２８９［４４．０４］
（２４７‐３２０）
＜０．０１２
＜０．００５
＜０．００５
０．００３
０．０５７５
０．６７１５
０．６０７１
０．８８８７
０．９８２０
０．００４０
０．０１１７
０．０４６
０．０１７９
＜０．００５
＜０．００５
DBP-Diastolic blood pressure
EF-ejection fraction
FSH-follicle stimulating hormone
HDL-high-density lipoprotein
LDL-low-density lipoprotein
LH-luteinizing hormone
Max-maximum value
Min-minimum value
NR-normal range
p-statistical significance
SBP-systolic blood pressure
SD-standard deviation
SHBG-sex hormone binding globulin
TG-triglycerides
Table３. Differences in laboratory findings between patients
without MI and controls
cases＝４０
[SD]
(Min‐Max)
controls＝２０
[SD]
(Min‐Max)
p
Total testosterone
(NR７．５‐３７．０）nmol/L
Free testosterone
(NR３７．４‐１３８．７pmol/L)
Free androgen index
(NR１８‐５０IU)
Oestradiol
(NR＜１８０pmol/L)
SHBG
(NR１５‐７５nmol/L)
LH
(NR１．３‐９．１IU/L)
FSH
(NR１．７‐１２．６IU/L)
EF
(NR＞７５％）
１２．０１［３．４］
（６．６‐１９．９）
２３．８５［５］
（３５‐５３）
２８．４［９．４］
（１６‐４４）
９３［３８．１６］
（２６．８‐２０２．１）
３３．４５［９．７５］
（１８‐４５）
３．２９［０．９１］
（２．８‐５．２）
５．７６［１．４３］
（４．２‐６．４９）
５１．８５［８．２２］
（３５‐６５）
２１．２［７．４］
（１５．７‐２６．８）
８６．１０［２８．４９］
（５４．００‐６７．００）
４７．３［１７．８］
（２１‐４９）
１４６．４［６６．５］
（８０．４‐１８４．０）
３１．３５［１１．２８］
（２３‐４０）
３．５６［１．６９］
（２．２８‐４．４３）
５．４５［０．８６］
（４．２６‐６．５４）
６１．３０［２３．３７］
（５６．００‐６５．００）
＜０．０１２
＜０．００５
＜０．００５
＜０．００３
０．０８４６
０．３４２６
０．７８９８
＜０．０５
EF-ejection fraction NR-normal range
FSH-follicle stimulating hormone ; LH-luteinizing hormone
Max-maximum value ; Min-minimum value
p-statistical significance ; SD-standard deviation ; SHBG-sex hormone binding
globulin
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results. English et al. did not find anycorrelation between
sex hormone levels and the intensity of atherosclerotic
lesion (7). A different method used in assessing the
extensiveness of atherosclerosismay have caused this
inconsistency in the results. The present study was
an observational one and experimental and clinical
human studies are clearly needed to verify the validity
of these present findings. Future investigations should
include amuch larger group of patients.Amajor action
of statins is to inhibit the synthesis of cholesterol in
different cells. Theoretically, lowering the cholesterol
levels can disrupt the steroid hormone synthesis. Such
an affect was not demonstrated in numerous clinical
trials. In the 4S examination, the rate ofmale impotency
was similar in the groups receiving statin treatment
and placebo.
Statin therapy wasmore frequently usedby coronary
heart patients but simultaneously total cholesterol
levels were higher than in the control group. Based
on this, the assumption that statin therapy decreases
endogenous testosterone precursor levels is groundless.
In addition, in clinical studies it has been shown that
such treatment did not affect steroidogenesis and
therefore does not influence testosterone levels (22).
Androgens in general are widely suggested to have
positive effectsonatherogenic lipidprofileby reducing the
levels of total cholesterol, LDL, VLDL and apolipoprotein
A1 (8, 23, 24). In thepresent studySHBGandendogenous
sex hormone levels were significantly correlated with
HDL and TG, respectively, but not with LDL and total
cholesterol levels. Unfortunately VLDL levels were
not considered because only 50% of the cases had been
measured.
SHBG correlated positively with HDL levels, and
negatively with TG levels (Table 4). Similar associations
were found with total testosterone but they did not
reach statistical significance. The opposite correlations
were observed in the case of free testosterone and FAI,
which correlated negatively with HDL and positively
with TG levels (Table 4). Most clinical studies assess
the influence of total, free testosterone on plasma lipids
underestimating the role of SHBG.Only in three studies
(25-27) have decreased levels of HDL and SHBG after
exogenous testosterone supplementationbeen reported.
Pugeat et al. suggested that SHBG increaseHDL levels
through aneffect onhepatic lipoprotein lipasebiosynthesis
(27). As suggested byGyllenborg et al., another possible
mechanism for SHBG influencingHDLmetabolism isby
some unidentified receptor. In thepresent investigation,
atherogenic lipid profile was associatedwith low levels
of SHBG and high levels of free testosterone. However
FAI and free testosterone levels were significantly
negatively associated with fibrinogen levels (Table 4).
This observation parallels findings fromprevious studies.
Bioavailable testosterone positively modifies coronary
heart disease riskprofileby itsdirect effect onendothelium
Table４. Correlations between sex hormone levels and variables
cases=Rp[p]
controls=Rp[p]
Total
testosterone
Free androgen index Free-testosterone SHBG Oestradiol
HDL ‐０．４３［０．６６］
（‐０．６［０．３４］）
‐０．８５［０．０４２］
（‐０．８９［０．０３１］）
‐０．８９［０．０３３］
（‐０．９１［０．００５］）
０．８６［０．０３４］
（０．９３［０．００２］）
０．７９［０．０２６］
（０．７６［０．０３７］）
TG ０．３２２［０．４５１］
（０．３６７［０．３９３］）
０．７８［０．０５３］
（０．８２［０．０４７］）
０．８１［０．０４８］
（０．９４［０．０３９］）
‐０．８７［０．０２１］
（‐０．９４［０．０１８］）
‐０．５６［０．３５４］
（‐０．６４［０．６７３］）
EF＊ ０．７３［０．０４９］
（０．７８［０．０４３］）
０．７６［０．０４２］
（０．８４［０．００４］）
０．９５［０．００２］
（０．８６［０．０４３］）
‐０．６５［０．２０２］
（０．７４［０．６３９］）
０．４５［０．６３２］
（０．８４［０．４３２］）
SBP ‐０．５［０．３２８］
（‐０．３４［０．４３１］）
‐０．７９［０．０４７］
（‐０．８９［０．００９］）
‐０．８７［０．０３７］
（‐０．８２［０．０４８］）
０．３２［０．７７１］
（０．５４［０．０７］）
‐０．７６［０．０５６］
‐０．８９［０．０４９］）
DBP ‐０．６７［０．２７８］
（‐０．７８［０．０８７］）
‐０．８９［０．０４６］
（‐０．９４［０．０３８］）
‐０．９３［０．０３４］
（‐０．８７［０．００５］）
０．５６［０．７８３］
０．７６［０．０７６］）
０．６２［０．０９２］
０．４６［０．５３９］）
Fibrinogen ‐０．７４［０．１７３］
（‐０．６７［０．４２９］）
‐０．７６［０．０４５］
（‐０．７８［０．０２８］）
‐０．８５［０．０２９］
（‐０．９４［０．００３］）
０．３２［０．２０２］
（０．５６［０．４９２］）
０．５９［０．４８２］
（０．７６［０．０８３］）
Duke Index ‐０．０７［０．５］ ‐０．７９［０．０６１］ ‐０．‐６９［０．０４８］ ‐０．１７［０．１４０］ ‐０．６７［０．０５］
＊cases n＝４０
EF-ejection fraction
DBP-diastolic blood pressure
HDL-high-density lipoprotein
p-statistical significance
SBP-systolic blood pressure
SHBG-sex hormone binding globulin ; TG-triglycerides
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and fibrinolysis (18, 29). Thus, it can be suggested that
endogenous sex hormone levels slow lesion progression
by influencing other, than plasma lipid, risk factors.
All this should be confirmed in well designed, double-
blind studies. Further investigations are necessary (30).
SHBG is a glycoprotein synthesised by hepar that
specifically binds approximately 60% of testosterone,
almost all 5α-dihydrotestosterone (DHT) and less then
40% of 17 β-oestradiol. Transporting sex hormones in
the blood vessels is not the sole function of SHBG. It
is responsible for the proper recognition of thedestination
cells and for the weakening of the biologic activity of
sex hormones. The high level of testosterone inhibits
the synthesis of SHBG, while oestradiol and thyroid
hormones act oppositely.
Levels of SHBG and oestradiol increase, whereas
levels of total and free testosterone decrease with
age. SHBG levels are higher in women than in men
of corresponding age. These differences diminish over
65 years old (31). Taking all this into consideration the
conclusion can be drawn that plasma lipid profile is
affected in a positive way by a rise in SHBG levels and
negatively by an increase in free testosterone levels.
In the present study, a significant differencewas noted
in the ejection fraction measurements between the
two groups. A comparison of cohorts was performed
after the exclusion of patients withMI. In the analyses
after adjustment for confounders (age, cigarette smoking,
and hypertension) the levels of total free testosterone
and oestradiol remained lower in coronary heart disease
patients (Table 3). There is no consensus on the effect
of endogenous sex hormones on ejection fraction. There
is no clinical trial findings concerning the effects of
testosterone on the left ventricular function. In rats,
testosterone, when administered intramuscularly
increases peak myocardial oxygen consumption and
attenuates sarcomers shortening thus improving theheart
function (20). Castration results in reduced ejection
fraction and diastolic dysfunction of the left ventricle.
LeGross et al. found that testosterone analogues taken
orally cause diastolic dysfunctionof theheart (32). Clinical
trials are needed to evaluate the effects of androgen
on the contractility of the heart.
In the present investigationendogenous sexhormone
levels negatively correlated with the extensiveness
of coronary atherosclerosis. This effect was multi-
dimensional and its aspects are not fully investigated.
Previous findings lack an unambiguous opinion on
the role of male sex hormones on the development
of the coronary atherosclerotic lesions. In the present
investigation endogenous sex hormones modified
several coronary heart disease risk factors. SHBG
levels negatively correlated with atherogenic plasma
lipid profile. Free testosterone levels correlatedpositively
with both, low fibrinogen levels and high ejection fraction
of the heart. Patients with higher levels of endogenous
sex hormones had significantly lower blood pressures,
with the strongest positive correlation between free
testosterone levels and diastolic blood pressure.
In conclusion, the results of the present investigation
suggest that :
1)SHBG may play a dominant role in influencing the
progression of lesions via the plasma lipid profile;
2)higher levels of free testosterone and FAI improve
the ejection fraction ;
3)higher levels ofmale sex hormoneswere associated
with patients with no atherosclerotic lesions ;
4)androgen replacement therapy can be useful in certain
male patients, especially elderly.
For some time, a renewal of interest in sexhormones
as cardioactive substances can be observed in the
world literature. The results of various studies are
slowly changing the views of male sex hormones
as a major coronary risk factor.
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